Paper. Bradley ER, Kelley P, Szigeti B et al.. JAMA Psychiatry, 21 Oct 2026.
Tags: Psilocybin, Neurological.
Psilocybin shifted inflammation markers in Parkinson's, in a trial with no control arm.
The JAMA Psychiatry report pairs psilocybin therapy with changes in systemic inflammatory and mitochondrial stress markers in people with Parkinson disease and mood symptoms — nonrandomized, so the markers cannot be attributed to the drug. Separately, a four-arm ayahuasca trial in 28 healthy volunteers (seven per arm) found no dose effect on intelligence and a single isolated interaction, on delayed recall.
How much weight it carries: One uncontrolled biomarker trial and one 28-person four-arm RCT; neither is powered to establish an effect, and the Parkinson's study cannot attribute change to psilocybin. (Humans, No control group, Small sample, RCT, Double-blind, Placebo-controlled, n = 28, Peer reviewed)
